Result of Secondary Placing

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has been informed by the Selling Shareholders that, further to the announcement made at 7 a.m. today (the "ABB Announcement"), they have successfully sold a total of 29,955,178 Placing Shares at a price of 28 pence per Placing Share. The Placing Shares in aggregate represent approximately 4.40 per cent. of the Company's issued share capital.

Capitalised terms in this announcement shall have the same meaning ascribed to them as in the ABB Announcement unless the context requires otherwise.

On completion of the Placing the Selling Shareholders, shall have the following resultant shareholdings:

Resultant holding

• Shares held by Cathal Friel are held through Raglan Road Capital Limited and Raglan Securities Limited, two companies owned and controlled by Cathal Friel, Pamela Iyer, Cathal Friel's spouse, and Horizon Medical Technologies Limited, an investment vehicle controlled by Cathal Friel.

The Selling Shareholders have agreed with Cavendish and Peel Hunt not to dispose of any further Ordinary Shares for a period of 12 months without the prior written consent of Cavendish and Peel Hunt.

The notification at the end of this announcement, set out in accordance with the requirements of MAR (as defined above), provides further details of the transactions.

The Placing was conducted through an accelerated bookbuild by Cavendish Capital Markets Limited ("Cavendish") and Peel Hunt LLP ("Peel Hunt") acting as placing agents. Proceeds of the Placing are payable in cash on usual settlement terms and the Placing is expected to settle on or around 21 February 2024.

Information to Distributors

Solely for the purposes of the product governance requirements of Chapter 3 of the FCA Handbook Product Intervention and Product Governance Sourcebook (the "UK Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the UK Product Governance Requirements) may otherwise have with respect thereto, the Placing Shares have been subject to a product approval process, which has determined that the Placing Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each defined in paragraph 3 of the FCA Handbook Conduct of Business Sourcebook; and (ii) eligible for distribution through all permitted distribution channels (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, "distributors" (for the purposes of the UK Product Governance Requirements) should note that: the price of the Placing Shares may decline and investors could lose all or part of their investment; the Placing Shares offer no guaranteed income and no capital protection; and an investment in the Placing Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to any contractual, legal or regulatory selling restrictions in relation to the Offer. Furthermore, it is noted that, notwithstanding the Target Market Assessment, Cavendish and Peel Hunt will only procure investors who meet the criteria of professional clients and eligible counterparties.